glp-1 obesity drug market news today GLP-1 Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 GLP-1 Receptor Agonist Market Size
Description
However, the ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial found that the once-daily GLP-1 receptor agonist lixisenatide had a neutral effect on cardiovascular outcomes, neither increasing nor decreasing incidence relative to placebo (31)
Despite their established benefits, these medications are often underprescribed, particularly in primary care settings where concerns about cost, complexity of use, and potential side effects persist
With obesity linked to hypertension, dyslipidemia, sleep apnea, cardiovascular disease, fatty liver disease, and kidney complications, GLP-1 drugs have become platform therapies rather than single-indication products
[47] Steinert, R
doi: 10.1016/j.jss.2025.05.016
